Apparatus for topical negative pressure therapy

Information

  • Patent Grant
  • 10561769
  • Patent Number
    10,561,769
  • Date Filed
    Monday, October 30, 2017
    7 years ago
  • Date Issued
    Tuesday, February 18, 2020
    4 years ago
Abstract
Apparatus and a method for the provision of TNP therapy to a wound are described, the apparatus comprising: a sealing membrane (504) for covering a wound to form a wound cavity (500); one end of an aspirant conduit (522) operably associated with the wound cavity, vacuum means (524) provided at a distal end of the aspirant conduit for applying a vacuum to the wound cavity; and, air bleed means (510) in fluid communication with the wound cavity. Various embodiments of air bleed port members are also described.
Description
TECHNICAL FIELD

The present invention relates to topical negative pressure (TNP) therapy particularly, though not exclusively, to the control of negative pressure within a wound dressing.


SUMMARY

TNP therapy has assumed great importance in recent years due to the beneficial effects of TNP therapy on a healing wound and also because of the accelerated healing which TNP therapy provides.


Apparatus for TNP therapy ranges from extremely complex apparatus only really suitable for use in a specialised hospital environment to much smaller and simpler, portable apparatus which may be used by an individual patient at home or at work.


The basic principle of TNP therapy is to create a closed cavity over the wound itself by means of a thin, flexible sealing film adhered to the patient's sound skin surrounding the wound; admitting one end of an aspirant conduit into the closed cavity, the conduit being sealed to the flexible film, for example; and connecting a distal end of the aspirant conduit to a vacuum source such as an electrically driven vacuum pump, for example, to create a pressure lower than the surrounding ambient atmospheric pressure within the wound cavity. As is known to the skilled person the lower pressure creates many beneficial therapeutic effects on the wound including increased blood flow to the wound and faster granulation of tissue, for example.


As noted above TNP therapy may be applied by a diverse range of apparatus. However, in general terms the more complex apparatus tends to be used on larger, more serious wounds which require a more intensive and varied treatments by TNP therapy. Examples of apparatus useful in the context of treatment of such larger wounds are given below.


In our co-pending International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.


In our co-pending International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, the invention described in this document utilises similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.


In our co-pending International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.


The content of the above references is included herein by reference.


However, the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.


Whilst the above examples are mainly relevant to the treatment of larger wounds, there is also a need for the treatment of relatively small wounds where the patient may otherwise be fit and mobile and require treatment outside of a clinical setting such as at home or at their workplace but where the provision of TNP therapy is desirable but nevertheless need to provide controlled conditions in the wound cavity. An example of a suitable apparatus is described in our co-pending UK patent application, GB0712736.8, of common ownership herewith, the content of which is included herein by reference.


An unexpected problem with smaller wounds of relatively low surface area is that they are relatively easy to seal in that they generally may have a relatively large area of sound flesh surrounding them and hence have large sealing borders therearound for the sealing film or drape to seal with and which tends to mitigate against inward air leaks from this area of the dressing. Secondly, even though the sealing films, which are well known to those skilled in the art, tend to be semi-permeable membrane type materials which allow to an extent the passage of gas such as air and water vapour, they do so only to a limited extent which is defined or measured in mass flow per unit area, Thus, since the area of the sealing film above the wound is relatively small, the amount of permitted gaseous flow is small. Because the seal over and around the wound may be very good, it is easy to create a vacuum in the wound cavity which does not decay quickly due to leaks, and therefore, very little or no flow through the aspirant conduit may result and whilst the vacuum is there over the wound, the wound exudate may not be being transported away to a waste canister, for example, and may be stagnating at the wound itself, this being especially so at low levels of negative pressure relative to atmospheric pressure. One important feature of TNP therapy is that the wound exudate fluid is desirably transported away from the wound site. Failure to achieve this efficiently may result in increased risk of infection and in the worst cases may result in back flow of wound exudate into the wound cavity.


However, whether the wound is large or small the fact is that clinicians strive to seal the wound as well as they possibly can so as to prevent bacteria from causing infection. Larger wounds generate greater volumes of fluid and, are therefore, susceptible to filling the wound cavity with fluid. Furthermore, it is possible for the aspiration conduit to fill with exudate fluid resulting in a pressure differential between the wound and the vacuum source due to the viscous drag of the exudate and the height differential between wound and vacuum source.


It is an object of the present invention to mitigate such problems especially, but not exclusively, in portable TNP therapy apparatus and to provide apparatus and a method where reliable flow of wound exudate away from the wound is promoted.


According to a first aspect of the present invention there is provided apparatus for the provision of TNP therapy to a wound, the apparatus comprising: a sealing membrane for covering a wound to form a wound cavity in use; an aspirant conduit having one end thereof operably associated with the wound cavity, in use; vacuum means provided at a distal end of the aspirant conduit for applying a vacuum to the wound cavity when in use; and, air bleed means in fluid communication with the wound cavity when in use.


In this specification the term “vacuum” means a pressure less than ambient atmospheric pressure.


The air bleed means may be switchable in that the air bleed may be turned on and off as desired. In this regard the air bleed means may be provided by a second conduit having one end in communication with the wound cavity and having a filter associated with the conduit and a clamp or valve which enables the filter to admit air from the surrounding atmosphere to the wound cavity under the influence of the vacuum in the wound cavity. Air flow into the conduit may be controlled by the clamp on the conduit or on/off valve controlled by the user/patient or a clinician. An air bleed may be admitted when, for example, the patient observes that the aspirant tube appears to be full of exudate but which is not moving. Opening of the conduit to ambient air then induces a fluid flow in the conduit to expel the exudate into a waste canister, for example, associated with particular TNP apparatus in use.


The air bleed means may provide a maximum flow rate at 200 mmHg below atmospheric of up to 1 l/min into the system. Preferably, the flow rate may be a maximum of 0.5 l/min. More preferably the flow rate may be a maximum of 0.2 l/min. More preferably still, a maximum flow rate of 0.05 l/min may be provided into the system. The overriding factor is to achieve a flow rate consistent with the wound not drying out as may happen if the incoming flow rate of bleed air is too high.


Control of bleed rate may be achieved by control of the area of the filter through which bleed air may be admitted.


Use of a filter is both desirable and advantageous in minimising the risk of pathogens from being admitted to the wound cavity by the air bleed.


The use of a regulator on the second conduit described above may also be employed to achieve a constant but controlled rate of inward air bleed.


Alternatively, the air bleed means may be associated with the sealing drape in which an aperture may be formed to permit the attachment of an air bleed port thereto. Such an air bleed port may have a filter portion or aperture through which ambient air is drawn into the wound cavity by the vacuum. Such an air bleed port may be permanently open to ambient atmosphere but, due to the contained filter portion, may restrict the rate of flow of air into the wound cavity or aspirant conduit to a low rate due to the size of the filter pores. In effect such an air bleed port substitutes for leakage of air into a TNP dressing which normally occurs with larger wounds. Suitable air bleed ports may be manufactured from soft plastics material mouldings so as not to cause trauma to a patient if lain upon. They may be provided during manufacture with a layer of adhesive thereon and suitable protective layer of siliconised paper until needed for use.


Such air bleed ports may be sealed off with suitable sealing tape so as to be able to check for leaks in the dressing and/or act as an on/off facility.


An air bleed provision may be provided by a second conduit plugged into a suitable grommet sandwiched between two adhesive drape or sealing membrane layers for example as described in our co-pending International patent application, PCT/US2007/074374, based on GB0712735.0, of common ownership herewith and the content of which are included herein by reference.


Suitable filters may be 0.2 or 0.1 or 0.02 micron filters, for example, which also have the added advantage in that they may also prevent expulsion of bacteria to atmosphere in the reverse direction if for any reason this might occur.


An advantage of the present invention is that use of a filter element of predetermined pore size and area permits close control of a desired low flow rate of ambient air into the wound cavity, the filter element itself also preventing ingress of potentially harmful bacteria. In contrast, conventional valves are insufficiently sensitive to control at the low flow rates required and also do not stop harmful bacterial from entering the wound.


In some embodiments of the present invention an air bleed port such as that described above may be provided with the drape or sealing membrane material during manufacture thereof, the air bleed port being adhered or welded to the drape or flexible sealing membrane.


In all embodiments of the present invention the rate of bleed air flow into the dressing and wound cavity is controlled solely by the characteristics of the filter with respect to its pore size and area exposed to ambient atmosphere.


According to a second aspect of the present invention there is provided an air bleed port member for use with a topical negative pressure dressing.


According to a third aspect of the present invention there is provided a method of providing topical negative pressure therapy to a wound, the method comprising the steps of: providing a sealing membrane for covering a wound to form a wound cavity; providing an aspirant conduit having one end thereof operably associated with the wound cavity; providing vacuum means provided at a distal end of the aspirant conduit for applying a vacuum to the wound cavity; and, air bleed means in fluid communication with the wound cavity.





BRIEF DESCRIPTION OF THE DRAWINGS

In order that the present invention may be more fully understood, examples will now be described by way of illustration only with reference to the accompanying drawings, of which:



FIG. 1 shows a schematic cross section through a wound to which TNP therapy is being applied and also showing schematically one embodiment of the present invention;



FIG. 2 shows across section through a schematic embodiment of a sealing membrane having an air bleed conduit and filter therewith; and



FIG. 3 shows a perspective view of a grommet for use in apparatus employing some embodiments of the present invention;



FIGS. 4A to 4D which show various views of an embodiment of an air bleed port for attachment to a sealing membrane;



FIG. 5 shows a schematic cross section through a second wound having an alternative air bleed port member attached to the sealing membrane;



FIGS. 6A to 6D show various views and a cross section s of the air bleed port shown in FIG. 5;



FIGS. 7A to 7F show various views and a cross section of a further alternative air bleed port for use with the dressing shown in FIG. 5;



FIGS. 8A to 8E show various views and a cross section through an alternative air bleed port suitable for the dressing shown in FIG. 1; and



FIGS. 9A and 9B which show a cross section and plan view, respectively of a further embodiment of a port member according to the present invention.





DETAILED DESCRIPTION

Referring now to the drawings and where the same features are designated by common reference numerals.



FIG. 1 shows a schematic cross section through a wound 10 to which is applied apparatus 12 according to the present invention for administering TNP therapy to the wound. The wound 10 has a sealing membrane 14 covering it and sealed to sound flesh 16 around the border of the wound so as to define a wound cavity 17. An aspirant conduit 18 is provided, the conduit having a perforated drain portion 20 and a single lumen portion 22 attached thereto and which is sealed to the dressing at 24 where it passes through. The distal end of the conduit 18 is connected to a suitable vacuum pump 26. The dressing is provided with a second, short conduit portion 30 which accesses the wound cavity 17 through the membrane 14 and sealed thereto at 32. The conduit 30 is provided with a pinch clamp 34 which enables the soft plastics material of the conduit 30 to be either closed or open for flow. At the end of the conduit 30 is a small plastics material housing 36 having an air inlet 38 an air outlet 40 and in between a filter element 42. Thus, air entering the inlet 38 must flow through the filter element 42 in order to flow through the outlet 40 and through the conduit 30. Optionally, there may be a layer of porous, compression resistant wound filler (not shown) adjacent the wound surface 10 to prevent the sealing membrane 14 from being pulled down onto the wound surface by the applied vacuum and thereby preventing flow of wound exudate to the aspirant drain conduit portion 20 from the whole area of the wound. However, in FIG. 1 which is meant to represent a small area wound such a wound filler may not be necessary if the sealing membrane is sufficiently taught not to contact the wound surface under the applied vacuum.


In operation the vacuum pump is turned on and a vacuum is created in the wound cavity 17. If the wound cavity is well sealed with no or very little leakage, wound exudate fluid may not be transported along the conduit portion 22 to a waste receptacle (not shown) associated with the vacuum pump 26 since there is little or no air/fluid flow along the conduit 22. In this event the pinch clamp 34 may be opened so that an air bleed is admitted through the filter element 42 into the wound cavity 17 thus stimulating a fluid flow through the wound cavity 17 and through the conduit 22 towards the pump 26 so keeping the conduit 22 unblocked and free flowing. The pinch clamp 34 has no effect on the flow rate of the air bleed, merely controlling whether there is or is not flow through the conduit 30, all flow control being decided by the pore size and area of the filter element 42.


In this instance the filter 42 is a 0.2 micron pore size, antimicrobial filter


The pinch clamp may be left open so that the conduit 30 is permanently open in the event that the wound cavity is particularly well sealed so providing a constant air bleed whilst the vacuum pump 26 is running.



FIG. 2 shows a schematic cross section of a dressing 100 for use with the apparatus according to the present invention and comprises a sealing membrane portion 102 and a conduit portion 104 having a filter housing 106 and having a filter 108 therein. The dressing 100 may be manufactured as an entity, the conduit portion 104 being attached by an adhesive layer 112 to a membrane member 114 at a flange portion 110 associated with the conduit portion 104. The lower face 116 of the adhesive layer 112 is protected in known manner by a layer of protective siliconised paper 118. In this dressing portion the membrane 114 covers the wound being adhered to sound flesh at the border thereof by the adhesive layer 112. The conduit 104 may optionally be provided with a pinch clamp, for example, as in the embodiment shown in FIG. 1 and for the same purpose.



FIG. 3 shows a conduit 200 of the type shown in FIGS. 1 and 2 but plugged into a grommet member 202. The grommet member has two curved faces 204,206 which meet at tapered edges 208, 210. This assembly of conduit 200 and grommet is incorporated into a dressing by the grommet member being sandwiched between two layers 212, 214 of thin, flexible adhesively coated membrane material where adhesive coated faces of the membrane material (not shown) face each other and adhere to the faces 204, 206 as discussed in our co-pending International patent application, PCT/US2007/074374, mentioned above and of common ownership herewith. Other embodiments of grommets from PCT/US2007/074374 may also be utilised.



FIG. 4 shows various views of an air bleed port member 300 for attachment to a sealing membrane (not shown). FIG. 4A shows a cross section through the port member; FIG. 4B shows a plan view of the port member; FIG. 4C shows a view in elevation; and, FIG. 4D shows a perspective view of the port member 300. The port member 300 comprises a moulded body portion 302 having a centrally disposed aperture 304 therethrough; an upper cap portion 306 having air ports 308 therethrough; and, a filter element member 310 sandwiched between the body portion and the cap portion. The cap portion 306 also has a circular recess 312 in fluid communication with the air ports 308, the filter element 310 being exposed to the area of the recess 312. The bottom face 314 of the body portion has a layer of adhesive 316 thereon and which is protected prior to use with protective paper layer 318 which is removed before use by means of a protruding finger tab 320.


To use the air bleed port member, a hole (not shown) is made in the membrane (not shown) covering the wound commensurate with the size of the aperture 304, the protective paper layer 318 us removed and the air bleed port 300 adhered to the upper surface of the sealing membrane with the hole in the membrane and the aperture 304 in communication with each other.


In a preferred construction the air bleed port 300 may be provided as part of a dressing membrane with the port 300 and membrane adhered or welded (in the latter case there is no adhesive layer 316) together during manufacture.



FIG. 5 shows a wound 500 having therein a porous, resiliently compressible wound filling element 502 such as a polyurethane foam material, for example, cut to conform generally to the wound shape and size. The wound 500 is covered with a self-adhesive flexible sealing membrane 504 similar to that shown in FIG. 1 and which is adhered to sound flesh 506 surrounding the wound 500. The membrane 504 has an aperture 508 formed therein and over which is adhered an air bleed port 510. The port 510 has a domed shape 512 having an aperture 514 in a flanged base portion 516, the aperture 514 being made coincident with the aperture 508 in the membrane 504. The port 510 has a socket portion 520 to receive an aspirant conduit 522 which is connected to a vacuum pump 524 and an intervening waste canister (not shown). The socket portion 520 receives the end of the aspirant conduit 522 to an extent which leaves uncovered an air bleed hole 528 which has a surrounding recess 530 into which is adhered a filter element 532. The wound surface 500, membrane 504 and air bleed port 510 form between them a sealed cavity 534.


In operation the vacuum pump 524 generates a predetermined vacuum level in the cavity 534 which causes the membrane 504 to be pushed down onto the porous, resiliently compressible wound filling element 502 by the ambient excess air pressure and the apertures 508, 514 to come into direct contact with the top surface of the resiliently compressible foam material 502 thus aspirating wound exudate which permeates through the wound filling element 502 to the waste canister (not shown). Whilst the wound exudate is being aspirated, the air bleed hole 528 and filter 532 permit a continuous controlled rate air bleed into the conduit 522 preventing the aspiration of wound exudate from stagnating. If, for any reason, it is desired to stop the air bleed then this can be terminated by the simple expedient of placing a piece of non-porous adhesive tape over the hole and filter 532.



FIG. 6 shows the air bleed port 510 of FIG. 5. FIG. 6A shows a top plan view of the port.



FIG. 6B shows a cross section on the line 6B-6B of FIG. 6A; FIG. 6C shows a view looking in the direction of arrow 6B on the left of FIG. 6A; and FIG. 6D shows a side view in elevation. The air bleed port 510 is generally of domed circular form having a hollow domed portion 512 and a socket portion 520 having a passage 540 leading into the hollow portion 542. The port comprises a flat flange portion 516 having an adhesive layer 544 to adhere to a flexible sealing membrane and the adhesive layer being protected before use by a layer of siliconised paper (not shown) in known manner. The lower face of the flange portion 516 has an aperture 514 therein exposing the hollow portion 542. The socket portion receives an aspirant conduit, in use, as described with reference to FIG. 5 and also has an air bleed hole 528 lying in the centre of recessed portion 530 which receives a filter member as shown in FIG. 5. The pore size of the filter member and, to an extent the size of the hole 528 control the rate of air bleed into the aspirant conduit at the desired pressure in the wound cavity 534 (see FIG. 5). The port 510 may be moulded from a soft plastics material such as polyurethane or polypropylene, for example.


The port described with reference to FIG. 6 may be adhered to a sealing membrane as described above or adhered or welded thereto in a pre-prepared sealing membrane and port unit.


An important advantage of the port according to the embodiment of FIG. 6 is that it is particularly easy to apply to a wound in that the self adhesive membrane material merely needs adhering to sound flesh after first having placed a wound filling element in the wound, an aperture made in the membrane and the port adhered thereto (or a pre formed port/membrane applied to the wound and an aspirant conduit plugged into the socket portion 520. There is no need to seal the aspirant conduit to the sealing membrane and the number of steps for making a TNP therapy dressing is significantly reduced.



FIG. 7 shows an air bleed port 600 which may also be used with the dressing described with reference to FIG. 5. FIG. 7A shows a top plan view of the port; FIG. 7B shows a cross section on the line 7B-7B of FIG. 7A; FIG. 7C shows a side view in elevation of the port of FIG. 7A; FIG. 7D shows an underside plan view of the port of FIG. 7A; FIG. 7E shows a perspective view of the port; and, FIG. 7F shows a view of the port in the direction of arrow 7B on the left of FIG. 7A. The port 600 is of generally circular form having a flange portion 602, a shallow domed body portion 604 lying within the flange periphery and a socket portion 606. The shallow domed body portion 604 is not hollow but has a number of splayed unequal length finger-like indentations 608 formed in the upper surface thereof as an aid to stiffness. The indentations extend almost through the thickness of the domed portion save for a predetermined thickness of material 610 remaining on the underside. On the underside the spaces between the indentations create a space 612 in which vacuum may exist and wound exudate collect to be aspirated away by an associated aspirant conduit (not shown) connected to the socket portion 606 in the same manner as with the port of FIG. 6. The socket portion 606 has a passage 614 therethrough leading to an aperture 616 which connects with a co-operating aperture, in use, in a sealing membrane. The socket portion has an air bleed hole 620 and a recessed portion 622 to receive a filter element (not shown) in the same manner as the port of FIG. 6. As with FIG. 6, the aspirant conduit is only inserted into the passage 614 up to the air bleed hole 620 so as not to block it.


This port also adheres to the sealing membrane surface or may be pre-prepared by adhering or welding the port thereto as a unit. Where the port member 600 has a layer of adhesive on the underside of flange portion 602 it may be provided with a protector layer of siliconised paper or PE film (not shown) to be removed by the user immediately before application to a flexible sealing membrane (not shown).


In use the port of FIG. 7 operates in the same manner as the port of FIG. 6 whereby the vacuum in the wound cavity cause the sealing membrane and port to be pushed down by excess ambient air pressure onto a porous and resiliently compressible wound filling element to provide a direct path for wound exudate to the aspirant conduit as shown and described with reference to FIG. 5.


Although resiliently compressible wound filling elements have been described above it is only necessary for the wound filling element to remain porous when the maximum desired vacuum is applied and it is not necessary that it also be resiliently compressible. The air bleed port of FIG. 7 has the same advantages as does the port of FIG. 6.



FIG. 8 shows an air bleed port 700 which is generally suitable for use with the type of wound dressing as shown in FIG. 1. FIG. 8A shows a perspective view of the port; FIG. 8B shows cross section in elevation of the port of FIG. 8A; FIG. 8C shows a view in elevation of the port of FIG. 8A along the line 8C; FIG. 8 D shows a top plan view of the port of FIG. 8A; and, FIG. 8E shows a cross section similar to that of FIG. 8B but with a portion of aspirant conduit inserted. The port 700 comprises an annular base flange portion 702 having a generally cylindrical wall portion 704 thereon. An angled tubular aspirant conduit receiving neck portion 706 supported on a bellows portion 708 is provided at the top of the wall portion 704. The wall portion 704 is provided with an air bleed hole 710 and a surrounding recess 712 to receive a filter element (not shown) as with other embodiments described above. The port 700 is moulded from a soft, flexible plastics material, the bellows portion 708 allowing the neck portion 706 to move and flex easily when an aspirant conduit 714 (see FIG. 8E) is in place. The port 700 may be used with the type of dressing shown in FIG. 1 where the aspirant conduit extends into the wound cavity 716 created between the wound bed and the sealing membrane 718. The end 720 of the conduit 714 may be associated with any desired item within the wound cavity such as a porous wound filling element whilst the other end 722 of the conduit 714 is connected to a waste canister and vacuum means (both not shown). The lower face 724 of the flange portion 702 is provided with an adhesive layer (not shown) to adhere to the sealing membrane 718 which has an aperture to coincide with an opening 730 in the annular base portion 702. The tubular neck portion 706 has an internal diameter to seal with the outer surface of the aspirant conduit 714.


In operation the wound cavity is evacuated to a desired pressure via the conduit 714 whilst a small but continuous air bleed through the hole 710 and filter in the recess 712 prevents wound exudate from stagnating due to a no-flow condition in the aspirant conduit 714. The flexible bellows portion 708 maintains the conduit 714 spaced-apart from the air bleed hole 710 thus preventing the hole from becoming blocked by the conduit surface due to the vacuum in the wound cavity.


As with previous embodiments the port 700 may be provided as a unit with a flexible sealing membrane by being adhered or welded thereto.


A further embodiment of an air bleed port member is shown in FIG. 9. The air bleed port member 800 comprises a patch of filter membrane 802 shown in FIG. 9B as circular (although it does not need to be round and could, for example, be rectangular) and having an annular layer of adhesive 804 applied to the outer periphery thereof, the adhesive being protected prior to use by protector papers 806. The adhesive layer prevents air bleed through that portion of the element which is coated with the adhesive. Therefore, by controlling the area of the filter membrane portion 810 coated with adhesive, the air bleed rate may be controlled through the uncoated portion 808 to an accurate level at a given pressure within a wound dressing. Thus, patches of filter membrane of a given size may be pre-coated with adhesive annuluses of varying widths or area allowing the user/clinician to choose the appropriate air bleed rate at the intended pressure.


Air bleed ports may be sterile packaged having an air bleed rate and associated pressure or pressure range printed thereon.


The air bleed port member of FIG. 9 may alternatively be pre-adhered or welded to a larger substrate layer of flexible sealing membrane as with other embodiments described above.


In the case of the port of FIG. 9 being welded to a flexible sealing membrane, the area of the filter membrane within the weld bead periphery would determine the air bleed flow rate. Thus, a range of air bleed port members welded to flexible sealing membranes may be prepared having different air bleed flow rates, the flexible sealing membrane having an aperture formed therein below the filter membrane portion through which air bleed occurs. In the case of the port being welded to a flexible sealing membrane the adhesive layer outside of the weld periphery may or may not be present.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

Claims
  • 1. A port member for connecting an aspirant conduit providing negative pressure with a topical negative pressure dressing, the port member comprising a housing, the housing comprising, within or as part of the housing: a base portion configured to be attached to a sealing membrane of the topical negative pressure dressing;an aperture in the base portion configured to communicate with a wound cavity under the dressing through an opening formed in the sealing membrane, wherein the port member is configured to be attached to the sealing membrane;a raised portion formed above the base portion and above the aperture;a connector portion extending away from the raised portion, wherein the connector portion extends in a direction substantially parallel to the base portion, and wherein a proximal end of the connector portion is configured to connect to a distal end of the aspirant conduit; anda passage within the housing, the passage having a distal end located at the aperture and a proximal end located at the proximal end of the connector portion; andan air bleed configured to bleed ambient air into the wound cavity when the port member is attached to the sealing membrane, the air bleed comprising an aeration orifice formed on the housing, wherein the orifice is laterally spaced from the aperture.
  • 2. The port member of claim 1, wherein the base portion and the raised portion are integrally formed.
  • 3. The port member of claim 1, wherein the raised portion defines a space in which vacuum may exist.
  • 4. The port member of claim 1, further comprises an aeration conduit having a first end configured to be in communication with the wound cavity and a second end spaced away from the wound cavity.
  • 5. The port member of claim 1, wherein the port member is configured to be provided the negative pressure in an upper portion of the port member.
  • 6. The port member of claim 1, wherein the air bleed further comprises a filter element positioned at the aeration orifice.
  • 7. The port member of claim 6, wherein the filter element is positioned above the aeration orifice.
  • 8. The port member of claim 6, wherein the filter element is attached to a portion of the housing adjacent the aeration orifice.
  • 9. The port member of claim 6, wherein the filter element is configured to control an air flow through the aeration orifice.
  • 10. The port member of claim 1, further comprising an aspirant conduit having a distal end thereof configured to be connected with the port member via the connector portion and a proximal end configured to be in fluid communication with a vacuum source for applying a vacuum through the aspirant conduit to the wound cavity when in use.
  • 11. The port member of claim 10, wherein the aspirant conduit extends away from the port member in a direction substantially parallel to the base portion when connected to the port member.
  • 12. The port member of claim 1, wherein the housing is manufactured from a soft plastic material.
  • 13. A port member for connecting an aspirant conduit providing negative pressure with a topical negative pressure dressing, the port member comprising: a body portion including a rim defining a lower surface of the body portion and a wall defining an upper surface of the body portion, wherein the wall is substantially domed;an aperture defined by the rim of the body portion, wherein the aperture is configured to communicate with a wound cavity under the dressing through an opening formed in the dressing, wherein the port member is configured to be attached to the dressing;a connector portion extending away from the body portion, the connector portion configured to connect to the aspirant conduit; andan aeration orifice extending through a portion of the wall.
  • 14. The port member of claim 13, further comprising an air flow restriction element provided to cover the aeration orifice, wherein the air flow restriction element is configured to open the aeration orifice temporarily or minimally open the aeration orifice permanently.
  • 15. The port member of claim 14, wherein the air flow restriction element comprises a filter element.
  • 16. The port member of claim 14, wherein the air flow restriction element comprises an adhesive tape configured to close the aeration orifice.
  • 17. The port member of claim 13, wherein the body portion defines a space in which vacuum may exist.
  • 18. The port member of claim 13, further comprising a flange formed below the body portion around the rim of the body portion, wherein the flange is configured to be attached to the wound dressing.
  • 19. The port member of claim 13, wherein the aeration orifice is laterally spaced from the aperture.
  • 20. The port member of claim 13, wherein the body portion is manufactured from a soft plastic material.
Priority Claims (1)
Number Date Country Kind
0723872.8 Dec 2007 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 14/221,045, filed on Mar. 20, 2014, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which is a continuation of U.S. patent application Ser. No. 12/746,458, filed on Jun. 4, 2010, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/GB2008/051118, filed on Nov. 26, 2008, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” which claims the benefit of Great Britain Application No. 0723872.8, filed Dec. 6, 2007, entitled “APPARATUS FOR TOPICAL NEGATIVE PRESSURE THERAPY,” the entire contents of each of which is hereby incorporated by reference herein in their entirety and for all purposes.

US Referenced Citations (295)
Number Name Date Kind
3382867 Reaves May 1968 A
3568675 Harvey Mar 1971 A
3633567 Sarnoff Jan 1972 A
3902484 Winters Sep 1975 A
3943734 Fleissner Mar 1976 A
4135515 Muriot Jan 1979 A
4306558 Kurtz et al. Dec 1981 A
4605399 Weston et al. Aug 1986 A
4710165 McNeil et al. Dec 1987 A
4822743 Wegrzyn Apr 1989 A
4869271 Idris Sep 1989 A
4903710 Jessamine Feb 1990 A
4921492 Schultz May 1990 A
4969880 Zamierowski Nov 1990 A
5042981 Gross Aug 1991 A
5088483 Heinecke Feb 1992 A
5100396 Zamierowski Mar 1992 A
5106362 Gilman Apr 1992 A
5154712 Herweck Oct 1992 A
5160315 Heinecke et al. Nov 1992 A
5180375 Feibus Jan 1993 A
5183763 Mallow Feb 1993 A
5218212 Sato Jun 1993 A
5261893 Zamierowski Nov 1993 A
5279550 Habib et al. Jan 1994 A
5358492 Feibus Oct 1994 A
5370610 Reynolds Dec 1994 A
5383476 Peimer Jan 1995 A
5386835 Elphick Feb 1995 A
5449347 Preen et al. Sep 1995 A
5466229 Elson Nov 1995 A
5520652 Peterson May 1996 A
5527293 Zamierowski Jun 1996 A
5531855 Heinecke et al. Jul 1996 A
5599289 Castellana Feb 1997 A
5599333 Atkinson Feb 1997 A
5618556 Johns et al. Apr 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5704905 Jensen Jan 1998 A
5735833 Olson Apr 1998 A
5738656 Wagner Apr 1998 A
5753285 Horan May 1998 A
5795584 Totakura et al. Aug 1998 A
5816252 Faries, Jr. Oct 1998 A
5885237 Kadash et al. Mar 1999 A
5911222 Lawrence et al. Jun 1999 A
5979226 Cavestri Nov 1999 A
6070454 Cavestri Jun 2000 A
6070455 Cavestri Jun 2000 A
6071267 Zamierowski Jun 2000 A
D430674 Dunshee et al. Sep 2000 S
6117111 Fleischmann Sep 2000 A
6142982 Hunt et al. Nov 2000 A
6149614 Dunshee et al. Nov 2000 A
6345623 Heaton Feb 2002 B1
6458109 Henley et al. Oct 2002 B1
6500112 Khouri Dec 2002 B1
6553998 Heaton Apr 2003 B2
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6685682 Heinecke et al. Feb 2004 B1
6695823 Lina Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6800074 Henley et al. Oct 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942687 Heaton et al. Sep 2005 B1
6951553 Bubb et al. Oct 2005 B2
6960190 Stinson Nov 2005 B2
D515701 Horhota et al. Feb 2006 S
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7070584 Johnson et al. Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7128735 Weston Oct 2006 B2
7195624 Lockwood Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7216651 Argenta et al. May 2007 B2
7279612 Heaton Oct 2007 B1
7316672 Hunt et al. Jan 2008 B1
7338482 Lockwood et al. Mar 2008 B2
7381859 Hunt et al. Jun 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7485112 Karpowicz et al. Feb 2009 B2
7503910 Adahan Mar 2009 B2
7524315 Blott et al. Apr 2009 B2
7531711 Sigurjonsson et al. May 2009 B2
7534927 Lockwood May 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7608066 Vogel Oct 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645269 Zamierowski Jan 2010 B2
7651484 Heaton et al. Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678102 Heaton Mar 2010 B1
7686785 Boehringer et al. Mar 2010 B2
7699830 Martin Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7709694 Batich May 2010 B2
7722582 Lina et al. May 2010 B2
7753894 Blott et al. Jul 2010 B2
7754936 Heaton et al. Jul 2010 B2
7776028 Miller et al. Aug 2010 B2
7794438 Henley et al. Sep 2010 B2
7794450 Blott et al. Sep 2010 B2
7858679 Messersmith Dec 2010 B2
7862718 Doyen et al. Jan 2011 B2
7880050 Robinson et al. Feb 2011 B2
7883494 Martin Feb 2011 B2
7909805 Weston Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7943380 Westman May 2011 B2
7951100 Hunt et al. May 2011 B2
7951124 Boehringer et al. May 2011 B2
7964766 Blott et al. Jun 2011 B2
7981098 Boehringer et al. Jul 2011 B2
7994383 Zocher Aug 2011 B2
7999145 Kairinos Aug 2011 B2
8002313 Singh et al. Aug 2011 B2
8021347 Vitaris et al. Sep 2011 B2
8057449 Sanders Nov 2011 B2
8062272 Weston Nov 2011 B2
8083712 Biggie et al. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston et al. Feb 2012 B2
8133211 Cavanaugh, II et al. Mar 2012 B2
8147468 Barta et al. Apr 2012 B2
8148595 Robinson et al. Apr 2012 B2
8152785 Vitaris Apr 2012 B2
8157775 Bobroff Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8187237 Seegert May 2012 B2
8188331 Barta et al. May 2012 B2
8202261 Kazala, Jr. et al. Jun 2012 B2
8211073 Dove Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8267908 Coulthard Sep 2012 B2
8282611 Weston Oct 2012 B2
8298200 Vess Oct 2012 B2
8303552 Weston Nov 2012 B2
8317774 Adahan Nov 2012 B2
8348910 Blott et al. Jan 2013 B2
8366692 Weston Feb 2013 B2
8376972 Fleischmann Feb 2013 B2
8382731 Johannison Feb 2013 B2
8430867 Robinson Apr 2013 B2
8449508 Coulthard et al. May 2013 B2
8449509 Weston May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8506554 Adahan Aug 2013 B2
8545466 Andresen et al. Oct 2013 B2
8641691 Fink Feb 2014 B2
8734410 Hall May 2014 B2
8771244 Eckstein et al. Jul 2014 B2
8784392 Vess Jul 2014 B2
8784393 Weston et al. Jul 2014 B2
8795243 Weston Aug 2014 B2
8801685 Armstrong et al. Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8915896 Sanders Dec 2014 B2
9017302 Vitaris et al. Apr 2015 B2
9033942 Vess May 2015 B2
9044579 Blott et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9227000 Fink et al. Jan 2016 B2
9302032 Bannister et al. Apr 2016 B2
9474654 Heagle et al. Oct 2016 B2
9801985 Hall Oct 2017 B2
20020044891 Miller Apr 2002 A1
20030040687 Boynton Feb 2003 A1
20030069529 Augustine et al. Apr 2003 A1
20030097100 Watson May 2003 A1
20030212357 Pace Nov 2003 A1
20040006319 Lina Jan 2004 A1
20040030304 Hunt Feb 2004 A1
20040200480 Faries, Jr. Oct 2004 A1
20040200483 Faries, Jr. Oct 2004 A1
20040208780 Faries, Jr. Oct 2004 A1
20040258562 Mills Dec 2004 A1
20050004534 Lockwood Jan 2005 A1
20050085795 Lockwood Apr 2005 A1
20050101940 Radl et al. May 2005 A1
20050112772 Farone May 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20060100586 Karpowicz May 2006 A1
20060155260 Blott Jul 2006 A1
20060194324 Faries, Jr. Aug 2006 A1
20070005028 Risk et al. Jan 2007 A1
20070016152 Karpowicz Jan 2007 A1
20070027423 Scheinberg et al. Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070038172 Zamierowski Feb 2007 A1
20070078366 Haggstrom Apr 2007 A1
20070078444 Larsson Apr 2007 A1
20070089753 Faries, Jr. Apr 2007 A1
20070156104 Lockwood et al. Jul 2007 A1
20070167926 Blott Jul 2007 A1
20070179460 Adahan Aug 2007 A1
20070219532 Karpowicz Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070260226 Jaeb et al. Nov 2007 A1
20070265586 Joshi Nov 2007 A1
20070282310 Bengtson et al. Dec 2007 A1
20080033325 Van der Hulst et al. Feb 2008 A1
20080071214 Locke Mar 2008 A1
20080071216 Locke et al. Mar 2008 A1
20080148817 Miller Jun 2008 A1
20080200906 Sanders et al. Aug 2008 A1
20080234641 Locke Sep 2008 A1
20090030383 Larsen et al. Jan 2009 A1
20090054855 Blott et al. Feb 2009 A1
20090131892 Karpowicz et al. May 2009 A1
20090157016 Adahan Jun 2009 A1
20090192467 Hansen et al. Jul 2009 A1
20090198201 Adahan Aug 2009 A1
20090221977 Blott et al. Sep 2009 A1
20090227969 Jaeb Sep 2009 A1
20090234309 Vitaris Sep 2009 A1
20090238811 McDaniel Sep 2009 A1
20090254053 Svensby et al. Oct 2009 A1
20090254066 Heaton Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299249 Wilkes et al. Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299257 Long et al. Dec 2009 A1
20090299308 Kazala et al. Dec 2009 A1
20090299340 Kazala et al. Dec 2009 A1
20090301382 Patel Dec 2009 A1
20090312723 Blott Dec 2009 A1
20100016767 Jones et al. Jan 2010 A1
20100022972 Lina et al. Jan 2010 A1
20100030167 Thirstrup Feb 2010 A1
20100069850 Fabo Mar 2010 A1
20100069863 Olson Mar 2010 A1
20100069886 Wilkes Mar 2010 A1
20100094234 Ramella et al. Apr 2010 A1
20100106114 Weston Apr 2010 A1
20100106117 Lockwood et al. Apr 2010 A1
20100106188 Heaton et al. Apr 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100125259 Olson May 2010 A1
20100160901 Hu et al. Jun 2010 A1
20100168691 Long et al. Jul 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100233146 McDaniel Sep 2010 A1
20100234818 Aali Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100262095 Hall Oct 2010 A1
20100324516 Braga et al. Dec 2010 A1
20110015619 Svedman Jan 2011 A1
20110028920 Johannison Feb 2011 A1
20110034888 Aali Feb 2011 A1
20110112492 Bharti May 2011 A1
20110118683 Weston May 2011 A1
20110130712 Topaz Jun 2011 A1
20110245682 Robinson Oct 2011 A1
20110250626 Williams Oct 2011 A1
20110251569 Turner et al. Oct 2011 A1
20110259086 Harris Oct 2011 A1
20110275159 Landgrebe Nov 2011 A1
20120095380 Gergley et al. Apr 2012 A1
20120109085 McNeil May 2012 A1
20120130332 Cotton et al. May 2012 A1
20120143155 Edvardsen Jun 2012 A1
20120143156 Bannister Jun 2012 A1
20120302976 Locke et al. Nov 2012 A1
20130066285 Locke Mar 2013 A1
20130150814 Buan Jun 2013 A1
20130172835 Braga et al. Jul 2013 A1
20130226152 Zolli Aug 2013 A1
20140088534 Kanakkanatt Mar 2014 A1
20140154808 Patel Jun 2014 A1
20140330225 Hall Nov 2014 A1
20140350494 Hartwell Nov 2014 A1
20150045752 Grillitsch et al. Feb 2015 A1
20150073358 Jaeb et al. Mar 2015 A1
20150141941 Allen May 2015 A1
20160158056 Davis Jun 2016 A1
Foreign Referenced Citations (145)
Number Date Country
674837 Jan 1997 AU
3 935 818 May 1991 DE
198 44 355 Apr 2000 DE
0 392 640 Jun 1995 EP
0 441 418 Jul 1995 EP
0 465 601 Jan 1997 EP
0 751 757 Jan 1997 EP
0 853 950 Jul 1998 EP
0 777 504 Oct 1998 EP
1 018 967 Jul 2000 EP
0 688 189 Sep 2000 EP
0 690 706 Nov 2000 EP
0 865 304 Jul 2001 EP
0 921 775 Dec 2001 EP
1 169 071 Jan 2002 EP
0 708 620 May 2003 EP
1 088 569 Aug 2003 EP
0 993 317 Sep 2003 EP
1 440 667 Jul 2004 EP
1 578 477 Jul 2004 EP
1 018 967 Aug 2004 EP
1 448 261 Aug 2004 EP
1 100 574 Feb 2005 EP
1 513 478 Mar 2005 EP
0 688 189 Jun 2005 EP
1 637 088 Mar 2006 EP
1 284 777 Apr 2006 EP
0 982 015 Aug 2006 EP
0 620 720 Nov 2006 EP
1 171 065 Mar 2007 EP
1 772 160 Apr 2007 EP
1 227 853 Jan 2008 EP
1 476 217 Mar 2008 EP
1 233 808 Jul 2008 EP
1 977 776 Oct 2008 EP
2 127 690 Dec 2009 EP
1 905 465 Jan 2010 EP
2 172 164 Apr 2010 EP
1 703 922 May 2011 EP
2 319 550 May 2011 EP
1 487 389 Oct 2011 EP
2 529 766 Dec 2012 EP
2 545 946 Mar 2013 EP
2 659 915 Nov 2013 EP
2 628 500 May 2014 EP
1 339 366 Jun 2014 EP
2 051 675 Jun 2014 EP
1 163 907 Oct 1958 FR
2307180 May 1997 GB
2329127 Mar 1999 GB
2336546 Oct 1999 GB
2344531 Jul 2000 GB
S61-80018 May 1986 JP
2005-334188 Dec 2005 JP
WO 1997018007 May 1997 WO
WO 199901173 Jan 1999 WO
WO 200021586 Apr 2000 WO
WO 2003030966 Apr 2003 WO
WO 2003045492 Jun 2003 WO
WO 2003057070 Jul 2003 WO
WO 2003086232 Oct 2003 WO
WO 2003092620 Nov 2003 WO
WO 2003101508 Dec 2003 WO
WO 2004037334 May 2004 WO
WO 2004060148 Jul 2004 WO
WO 200504670 Jan 2005 WO
WO 2005016179 Feb 2005 WO
WO 2005061025 Jul 2005 WO
WO 2005105174 Nov 2005 WO
WO 2005105180 Nov 2005 WO
WO 2006052338 May 2006 WO
WO 2006052745 May 2006 WO
WO 2007006306 Jan 2007 WO
WO 2007013049 Feb 2007 WO
WO 2007013064 Feb 2007 WO
WO 2007016590 Feb 2007 WO
WO 2007019038 Feb 2007 WO
WO 2007041642 Apr 2007 WO
WO 2007067685 Jun 2007 WO
WO 2007085396 Aug 2007 WO
WO 2007087810 Aug 2007 WO
WO 2007092397 Aug 2007 WO
WO 2007095180 Aug 2007 WO
WO 2007106590 Sep 2007 WO
WO 2007106591 Sep 2007 WO
WO 2008008032 Jan 2008 WO
WO 2008010094 Jan 2008 WO
WO 2008012278 Jan 2008 WO
WO 2008027449 Mar 2008 WO
WO 2008030872 Mar 2008 WO
WO 2008036360 Mar 2008 WO
WO 2008039314 Apr 2008 WO
WO 2008043067 Apr 2008 WO
WO 2008048481 Apr 2008 WO
WO 2008100437 Aug 2008 WO
WO 2008100440 Aug 2008 WO
WO 2008100446 Aug 2008 WO
WO 2008131895 Nov 2008 WO
WO 2008135997 Nov 2008 WO
WO 2008141470 Nov 2008 WO
WO 2009002260 Dec 2008 WO
WO 2009019419 Feb 2009 WO
WO 2009019495 Feb 2009 WO
WO 2009066104 May 2009 WO
WO 2009068665 Jun 2009 WO
WO 2009071933 Jun 2009 WO
WO 2009086580 Jul 2009 WO
WO 2009088925 Jul 2009 WO
WO 2009089390 Jul 2009 WO
WO 2009111655 Sep 2009 WO
WO 2009126103 Oct 2009 WO
WO 2009137194 Nov 2009 WO
WO 2009140376 Nov 2009 WO
WO 2009141820 Nov 2009 WO
WO 2009145894 Dec 2009 WO
WO 2009158125 Dec 2009 WO
WO 2009158126 Dec 2009 WO
WO 2009158127 Dec 2009 WO
WO 2009158129 Dec 2009 WO
WO 2010014177 Feb 2010 WO
WO 2010033271 Mar 2010 WO
WO 2010033272 Mar 2010 WO
WO 2010033769 Mar 2010 WO
WO 2010042240 Apr 2010 WO
WO 2010051073 May 2010 WO
WO 2010059712 May 2010 WO
WO 2010059730 May 2010 WO
WO 2010078166 Jul 2010 WO
WO 2010120470 Oct 2010 WO
WO 2010147533 Dec 2010 WO
WO 2011049562 Apr 2011 WO
WO 2011100851 Aug 2011 WO
WO 2011115908 Sep 2011 WO
WO 2012142002 Oct 2012 WO
WO 2012166428 Dec 2012 WO
WO 2012174672 Dec 2012 WO
WO 2013013938 Jan 2013 WO
WO 2013016239 Jan 2013 WO
WO 2013019438 Feb 2013 WO
WO 2013043972 Mar 2013 WO
WO 2013123005 Aug 2013 WO
WO 2014066057 May 2014 WO
WO 2014043238 Sep 2014 WO
WO 2014158526 Oct 2014 WO
WO 2015018720 Feb 2015 WO
Non-Patent Literature Citations (15)
Entry
US 7,186,244 B1, 03/2007, Hunt et al. (withdrawn)
International Preliminary Report on Patentability, re PCT Application No. PCT/GB2008/051118, dated Jun. 8, 2010.
Boehringer Wound Systems, LLC, Engenex™ Instructions for Use, Aug. 2007, pp. 1-33.
Edlich, R. F. et al., “Evaluation of a New, Improved Surgical Drainage System”, The American Journal of Surgery, vol. 149, Issue 2, Feb. 1985, pp. 295-298.
Info V.A.C. User Manual—KCI—Dec. 2006, in 76 pages.
International Search Report, re PCT Application No. PCT/GB2008/050507, dated Oct. 15, 2008.
International Search Report, re PCT Application No. PCT/GB2008/051118, dated Jun. 19, 2009.
Smith, S.R.G., “Surgical Drainage,” British Journal of Hospital Medicine, Jun. 1985, pp. 308-315.
Van Way III, MD, Charles W., “Prevention of sunction-induced gastric mucosal damage in dogs,” Critical Care Medicine, 1987, pp. 774-777, vol. 15, No. 8.
Worth, M.H., M.D. and H.W. Anderson, M.D., “The Effectiveness of Bacterial Filtration in Vented Wound Drains,” Journal of Surgical Research, 1979, pp. 405-407.
Annex to the Communication, re the Opposition of European Patent No. EP 2 231 218, dated Apr. 17, 2019, in 10 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition of European Patent No. EP 2 231 218, dated Dec. 18, 2018, in 24 pages.
Reply of the Patent Proprietor to the Notice(s) of Opposition, re the Opposition of European Patent No. EP 2 231 218, dated Nov. 28, 2018, in 26 pages.
Communication of a Notice of Opposition including Statement of Facts and Evidence, re European Patent No. EP 2 231 218, dated Jul. 2, 2018, in 17 pages.
Notice of Opposition—Statement of Facts and Evidence, re European Patent No. EP 2 231 218, dated Jun. 21, 2018, in 16 pages.
Related Publications (1)
Number Date Country
20180126051 A1 May 2018 US
Continuations (2)
Number Date Country
Parent 14267721 May 2014 US
Child 15797899 US
Parent 12746458 US
Child 14267721 US